Interestingly, the IBD therapeutic effects of vidofludimus were not observed in FXR KO mice, suggesting the functional importance of FXR in the pharmacological pathway of this immunomodulatory drug candidate. This evidence concerns the gene NR1H4 and inflammatory bowel disease.